The PI3K/Akt Pathway in Tumors of Endocrine Tissues

Neuroblastoma: Molecular Pathogenesis and Therapy

(2015) Chrystal U. Louis et al.   Annual Review of Medicine

Akt/PKB: one kinase, many modifications

(2015) Guillermo Risso et al.   BIOCHEMICAL JOURNAL

Diagnosis, treatment and outcome of adrenocortical cancer

(2015) R. Mihai   BRITISH JOURNAL OF SURGERY

Mitogen-Activated Protein Kinase Pathway: Genetic Analysis of 95 Adrenocortical Tumors

(2015) Beatrice Rubin et al.   CANCER INVESTIGATION

Targeting PI3K/mTOR Signaling Displays Potent Antitumor Efficacy against Nonfunctioning Pituitary Adenomas

(2015) M. Lee et al.   CLINICAL CANCER RESEARCH

The PDCD4/miR-21 pathway in medullary thyroid carcinoma

(2015) Gianmaria Pennelli et al.   HUMAN PATHOLOGY

Role of X-Linked Inhibitor of Apoptosis as a Prognostic Marker and Therapeutic Target in Papillary Thyroid Carcinoma

(2015) Azhar R. Hussain et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Critical roles of specimen type and temperature before and during fixation in the detection of phosphoproteins in breast cancer tissues

(2015) Sibylle Gündisch et al.   LABORATORY INVESTIGATION

Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study

(2015) Martin Fassnacht et al.   LANCET ONCOLOGY

SUMO modification of Akt regulates global SUMOylation and substrate SUMOylation specificity through Akt phosphorylation of Ubc9 and SUMO1

(2015) C H Lin et al.   ONCOGENE

The Dual mTORC1 and mTORC2 Inhibitor PP242 Shows Strong Antitumor Activity in a Pheochromocytoma PC12 Cell Tumor Model

(2015) Xiaohua Zhang et al.   UROLOGY

Loss of β-catenin in adrenocortical cancer cells causes growth inhibition and reversal of epithelial-to-mesenchymal transition

(2015) Aude Salomon et al.   Oncotarget

Oncogenic features of the bone morphogenic protein 7 (BMP7) in pheochromocytoma

(2015) Ines Leinhäuser et al.   Oncotarget

The prognostic value of phosphorylated Akt in breast cancer: a systematic review

(2015) Zu-Yao Yang et al.   Scientific Reports

GSK-3 as potential target for therapeutic intervention in cancer

(2015) James A. McCubrey et al.   Oncotarget

Turning Off AKT: PHLPP as a Drug Target

(2014) Alexandra C. Newton et al.   Annual Review of Pharmacology and Toxicology

Progesterone Receptor and PTEN Expression Predict Survival in Patients With Low- and Intermediate-Grade Pancreatic Neuroendocrine Tumors

(2014) Jeannelyn S. Estrella et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma

(2014) Maqbool Ahmed et al.   CARCINOGENESIS

Integrated Genomic Characterization of Papillary Thyroid Carcinoma

(2014) Nishant Agrawal et al.   CELL

Influence of Biospecimen Variables on Proteomic Biomarkers in Breast Cancer

(2014) F. Meric-Bernstam et al.   CLINICAL CANCER RESEARCH

Roles of the Pathologist in Evaluating Surrogate Markers for Medical Therapy in Adrenocortical Carcinoma

(2014) Hironobu Sasano et al.   ENDOCRINE PATHOLOGY

The PI3K/AKT/mTOR pathway in the pathophysiology and treatment of pituitary adenomas

(2014) Eric Monsalves et al.   ENDOCRINE-RELATED CANCER

Follicular Thyroid Cancers Demonstrate Dual Activation of PKA and mTOR as Modeled by Thyroid-Specific Deletion ofPrkar1aandPtenin Mice

(2014) Daphne R. Pringle et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Suppression of Feedback Loops Mediated by PI3K/mTOR Induces Multiple Overactivation of Compensatory Pathways: An Unintended Consequence Leading to Drug Resistance

(2014) E. Rozengurt et al.   MOLECULAR CANCER THERAPEUTICS

Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus

(2014) Pengda Liu et al.   NATURE

PI3K and cancer: lessons, challenges and opportunities

(2014) David A. Fruman et al.   NATURE REVIEWS DRUG DISCOVERY

COSMIC: exploring the world's knowledge of somatic mutations in human cancer

(2014) Simon A. Forbes et al.   NUCLEIC ACIDS RESEARCH

Activation of the PI3K/mTOR/AKT Pathway and Survival in Solid Tumors: Systematic Review and Meta-Analysis

(2014) Alberto Ocana et al.   PLoS One

SIN1, a critical component of the mTOR-Rictor complex, is overexpressed and associated with AKT activation in medullary and aggressive papillary thyroid carcinomas

(2014) Dimitrios Moraitis et al.   SURGERY

Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma

(2014) Zorica Milosevic et al.   Translational Research

The Genetic Basis of Pheochromocytoma and Paraganglioma: Implications for Management

(2014) Brian Shuch et al.   UROLOGY

The Combination of Insulin-Like Growth Factor Receptor 1 (IGF1R) Antibody Cixutumumab and Mitotane as a First-Line Therapy for Patients with Recurrent/Metastatic Adrenocortical Carcinoma: a Multi-institutional NCI-Sponsored Trial

(2014) Antonio M. Lerario et al.   Hormones & Cancer

Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma

(2013) A Naing et al.   BRITISH JOURNAL OF CANCER

PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors

(2013) Edward M. Wolin   CANCER LETTERS

FOXO3a Is a Major Target of Inactivation by PI3K/AKT Signaling in Aggressive Neuroblastoma

(2013) E. E. Santo et al.   CANCER RESEARCH

Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068

(2013) Y. Yan et al.   CLINICAL CANCER RESEARCH

mTOR is Frequently Active in GH-Secreting Pituitary Adenomas without Influencing their Morphopathological Features

(2013) Emir Ahmed Sajjad et al.   ENDOCRINE PATHOLOGY

Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature

(2013) M Fraenkel et al.   ENDOCRINE-RELATED CANCER

Inhibition of PI3K/AKT/mTOR Pathway Enhances Temozolomide-Induced Cytotoxicity in Pituitary Adenoma Cell Lines in Vitro and Xenografted Pituitary Adenoma in Female Nude Mice

(2013) Congxin Dai et al.   ENDOCRINOLOGY

Combined Inhibition of mTORC1 and mTORC2 Signaling Pathways Is a Promising Therapeutic Option in Inhibiting Pheochromocytoma Tumor Growth: In Vitro and In Vivo Studies in Female Athymic Nude Mice

(2013) Alessio Giubellino et al.   ENDOCRINOLOGY

Mutational analyses of epidermal growth factor receptor and downstream pathways in adrenocortical carcinoma

(2013) Ilse G C Hermsen et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

The genomic landscape of small intestine neuroendocrine tumors

(2013) Michaela S. Banck et al.   JOURNAL OF CLINICAL INVESTIGATION

Prognostic Significance of MTOR Pathway Component Expression in Neuroendocrine Tumors

(2013) Zhi Rong Qian et al.   JOURNAL OF CLINICAL ONCOLOGY

Complete genomic landscape of a recurring sporadic parathyroid carcinoma

(2013) Katayoon Kasaian et al.   JOURNAL OF PATHOLOGY

Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies

(2013) Deepa Sampath et al.   LEUKEMIA RESEARCH

Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis

(2013) Pengda Liu et al.   NATURE CELL BIOLOGY

Akt2 Regulates Metastatic Potential in Neuroblastoma

(2013) Jingbo Qiao et al.   PLoS One

Germline PIK3CA and AKT1 Mutations in Cowden and Cowden-like Syndromes

(2012) Mohammed S. Orloff et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Neuroendocrine bronchial and thymic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2012) K. Oberg et al.   ANNALS OF ONCOLOGY

Neuroendocrine phenotype alteration and growth suppression through apoptosis by MK-2206, an allosteric inhibitor of AKT, in carcinoid cell lines in vitro

(2012) Yash Somnay et al.   ANTI-CANCER DRUGS

The emerging multiple roles of nuclear Akt

(2012) Alberto M. Martelli et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Mutation and genomic amplification of the PIK3CA proto-oncogene in pituitary adenomas

(2012) C.B. Murat et al.   BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH

PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors

(2012) F. Meric-Bernstam et al.   CLINICAL CANCER RESEARCH

Activation of the mTOR Pathway in Primary Medullary Thyroid Carcinoma and Lymph Node Metastases

(2012) A. Tamburrino et al.   CLINICAL CANCER RESEARCH

Genetic aspects of adrenocortical tumours and hyperplasias

(2012) Tânia L. Mazzuco et al.   CLINICAL ENDOCRINOLOGY

Biomarkers of Parathyroid Carcinoma

(2012) Boban M. Erovic et al.   ENDOCRINE PATHOLOGY

Prognostic and Predictive Markers in Medullary Thyroid Carcinoma

(2012) Boban M. Erovic et al.   ENDOCRINE PATHOLOGY

The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells

(2012) Maria Cristina De Martino et al.   ENDOCRINE-RELATED CANCER

Perifosine-mediated Akt inhibition in neuroendocrine tumor cells: role of specific Akt isoforms

(2012) Kathrin Zitzmann et al.   ENDOCRINE-RELATED CANCER

Combination of sorafenib and everolimus impacts therapeutically on adrenocortical tumor models

(2012) Barbara Mariniello et al.   ENDOCRINE-RELATED CANCER

CD133 expression is associated with poor outcome in neuroblastoma via chemoresistance mediated by the AKT pathway

(2012) Hervé Sartelet et al.   HISTOPATHOLOGY

Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors

(2012) Michael H�pfner   INTERNATIONAL JOURNAL OF ONCOLOGY

PI3K-independent AKT activation in cancers: A treasure trove for novel therapeutics

(2012) Kiran Mahajan et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Low SGK1 Expression in Human Adrenocortical Tumors Is Associated with ACTH-Independent Glucocorticoid Secretion and Poor Prognosis

(2012) Cristina L. Ronchi et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in a preclinical model of adrenocortical carcinoma

(2012) Mabrouka Doghman et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Secretin Receptor Promotes the Proliferation of Endocrine Tumor Cells Via the PI3K/AKT Pathway

(2012) Misu Lee et al.   MOLECULAR ENDOCRINOLOGY

Functional screen analysis reveals miR-26b and miR-128 as central regulators of pituitary somatomammotrophic tumor growth through activation of the PTEN–AKT pathway

(2012) T Palumbo et al.   ONCOGENE

Invasion in follicular thyroid cancer cell lines is mediated by EphA2 and pAkt

(2012) Yunxia O’Malley et al.   SURGERY

Immunohistochemical Evidence of Dysregulation of the Mammalian Target of Rapamycin Pathway in Primary and Metastatic Pheochromocytomas

(2012) Alcides Chaux et al.   UROLOGY

RET/PTC Translocations and Clinico-Pathological Features in Human Papillary Thyroid Carcinoma

(2012) Cristina Romei et al.   Frontiers in Endocrinology

Sunitinib induces apoptosis in pheochromocytoma tumor cells by inhibiting VEGFR2/Akt/mTOR/S6K1 pathways through modulation of Bcl-2 and BAD

(2011) Yuria Saito et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

FoxO transcription factors; Regulation by AKT and 14-3-3 proteins

(2011) Guri Tzivion et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Akt phosphorylation on Thr308 but not on Ser473 correlates with Akt protein kinase activity in human non-small cell lung cancer

(2011) E E Vincent et al.   BRITISH JOURNAL OF CANCER

Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT

(2011) Bernhard Svejda et al.   CANCER

Identification of PHLPP1 as a Tumor Suppressor Reveals the Role of Feedback Activation in PTEN-Mutant Prostate Cancer Progression

(2011) Muhan Chen et al.   CANCER CELL

Akt signalling in health and disease

(2011) Ingeborg Hers et al.   CELLULAR SIGNALLING

Expression, Localization, and Phosphorylation of Akt1 in Benign and Malignant Thyroid Lesions

(2011) Anna Krześlak et al.   ENDOCRINE PATHOLOGY

Transcriptome analysis of adrenocortical cancers (ACC): from molecular classification to the identification of new treatments

(2011) B. Ragazzon et al.   ENDOCRINE-RELATED CANCER

Inhibition of gap junction transfer sensitizes thyroid cancer cells to anoikis

(2011) Kirk Jensen et al.   ENDOCRINE-RELATED CANCER

The Phosphatase PHLPP1 Regulates Akt2, Promotes Pancreatic Cancer Cell Death, and Inhibits Tumor Formation

(2011) Claudia Nitsche et al.   GASTROENTEROLOGY

mTOR Activation in Well Differentiated Pancreatic Neuroendocrine Tumors: A Retrospective Study on 34 Cases

(2011) Chen-Fei Zhou et al.   HEPATO-GASTROENTEROLOGY

Activation of the phosphatidylinositol 3′-kinase/AKT pathway in neuroblastoma and its regulation by thioredoxin 1

(2011) Hervé Sartelet et al.   HUMAN PATHOLOGY

Mammalian Target of Rapamycin Pathway Activation Is Associated to RET Mutation Status in Medullary Thyroid Carcinoma

(2011) Ida Rapa et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Incidence and Clinical Characteristics of Thyroid Cancer in Prospective Series of Individuals with Cowden and Cowden-Like Syndrome Characterized by GermlinePTEN,SDH, orKLLNAlterations

(2011) Joanne Ngeow et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors

(2011) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

Morphoproteomics demonstrates activation of mammalian target of rapamycin pathway in papillary thyroid carcinomas with nuclear translocation of MTOR in aggressive histological variants

(2011) Jing Liu et al.   MODERN PATHOLOGY

Levels of p27 Sensitize to Dual PI3K/mTOR Inhibition

(2011) M. Lee et al.   MOLECULAR CANCER THERAPEUTICS

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

(2011) James C. Yao et al.   NEW ENGLAND JOURNAL OF MEDICINE

New targeted therapies in pituitary carcinoma resistant to temozolomide

(2011) Emmanuel Jouanneau et al.   Pituitary

DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors

(2011) Y. Jiao et al.   SCIENCE

The Somatostatin Analogue Octreotide Confers Sensitivity to Rapamycin Treatment on Pituitary Tumor Cells

(2010) V. Cerovac et al.   CANCER RESEARCH

Mutational and Immunohistochemical Study of the PI3K/Akt Pathway in Papillary Thyroid Carcinoma in Greece

(2010) Elias Sozopoulos et al.   ENDOCRINE PATHOLOGY

Molecular markers associated with response to chemotherapy in gastro-entero-pancreatic neuroendocrine tumors

(2010) Dermot O'Toole et al.   ENDOCRINE-RELATED CANCER

mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours

(2010) A. Kasajima et al.   ENDOCRINE-RELATED CANCER

High level of apoptosis and low AKT activation in mass screening as opposed to standard neuroblastoma

(2010) Hervé Sartelet et al.   HISTOPATHOLOGY

Distinct Regulation of Intrinsic Apoptosis in Benign and Malignant Thyroid Tumours

(2010) C. Weidinger et al.   HORMONE AND METABOLIC RESEARCH

VEGFR-2 expression in carcinoid cancer cells and its role in tumor growth and metastasis

(2010) Scott R. Silva et al.   INTERNATIONAL JOURNAL OF CANCER

Spectrum and Prevalence of FP/TMEM127 Gene Mutations in Pheochromocytomas and Paragangliomas

(2010) Li Yao et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Involvement of PTEN/Akt signaling in capsular invasive carcinomas developed in a rat two-stage thyroid carcinogenesis model after promotion with sulfadimethoxine

(2010) Sayaka Kemmochi et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Possible Relevance between Prohormone Convertase 2 Expression and Tumor Growth in Human Adrenocorticotropin-Producing Pituitary Adenoma

(2010) Kazumi Iino et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2

(2010) Niamh H Foley et al.   Molecular Cancer

Germline mutations in TMEM127 confer susceptibility to pheochromocytoma

(2010) Yuejuan Qin et al.   NATURE GENETICS

Recent Advances in Neuroblastoma

(2010) John M. Maris   NEW ENGLAND JOURNAL OF MEDICINE

CD133 suppresses neuroblastoma cell differentiation via signal pathway modification

(2010) H Takenobu et al.   ONCOGENE

PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis

(2010) A Bender et al.   ONCOGENE

Utilidad del análisis inmunohistoquímico de diversos marcadores moleculares en la caracterización del carcinoma papilar de tiroides con metástasis linfáticas iniciales

(2010) Carles Zafón et al.   Endocrinologia y Nutricion

Inhibition of Phosphatidylinositol 3-Kinase/Akt Signaling Suppresses Tumor Cell Proliferation and Neuroendocrine Marker Expression in GI Carcinoid Tumors

(2009) Susan C. Pitt et al.   ANNALS OF SURGICAL ONCOLOGY

Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma

(2009) Paul Haluska et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors

(2009) Takashi Shida et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Mutational Profile of Advanced Primary and Metastatic Radioactive Iodine-Refractory Thyroid Cancers Reveals Distinct Pathogenetic Roles for BRAF, PIK3CA, and AKT1

(2009) J. C. Ricarte-Filho et al.   CANCER RESEARCH

An Analysis of Potential Surrogate Markers of Target-Specific Therapy in Archival Materials of Adrenocortical Carcinoma

(2009) Megumi Nakamura et al.   ENDOCRINE PATHOLOGY

Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors

(2009) D Dworakowska et al.   ENDOCRINE-RELATED CANCER

Novel and Evolving Therapies in the Treatment of Malignant Phaeochromocytoma: Experience with the mTOR Inhibitor Everolimus (RAD001)

(2009) M. R. Druce et al.   HORMONE AND METABOLIC RESEARCH

Predicting Recurrence of Nonfunctioning Pituitary Adenomas

(2009) Tae-Woong Noh et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effect of Everolimus on Cell Viability in Nonfunctioning Pituitary Adenomas

(2009) Maria Chiara Zatelli et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Pancreatic Endocrine Tumors: Expression Profiling Evidences a Role for AKT-mTOR Pathway

(2009) Edoardo Missiaglia et al.   JOURNAL OF CLINICAL ONCOLOGY

The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors

(2009) Motoyasu Saji et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Targeting the phosphoinositide 3-kinase pathway in cancer

(2009) Pixu Liu et al.   NATURE REVIEWS DRUG DISCOVERY

INHIBITION OF NFκB REDUCES CELLULAR VIABILITY IN GH3 PITUITARY ADENOMA CELLS

(2009) John R. Vender et al.   NEUROSURGERY

Inhibition of the PI3K Pathway Suppresses Hormonal Secretion and Limits Growth in Pheochromocytoma Cells

(2009) Joel T. Adler et al.   WORLD JOURNAL OF SURGERY

Current overview of the role of Akt in cancer studies via applied immunohistochemistry

(2008) Viktor Shtilbans et al.   Annals of Diagnostic Pathology

FOXO3a: a novel player in thyroid carcinogenesis?

(2008) Stefan Karger et al.   ENDOCRINE-RELATED CANCER

Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors

(2008) Yong Lin et al.   ENDOCRINE-RELATED CANCER

Activation of Phosphatidylinositol 3-Kinase Signaling Promotes Aberrant Pituitary Growth in a Mouse Model of Thyroid-Stimulating Hormone-Secreting Pituitary Tumors

(2008) Changxue Lu et al.   ENDOCRINOLOGY

Epidermal Growth Factor Receptor Pathway Substrate 8 Is Overexpressed in Human Pituitary Tumors: Role in Proliferation and Survival

(2008) Mei Xu et al.   ENDOCRINOLOGY

Dysregulation of the Phosphatidylinositol 3-Kinase Pathway in Thyroid Neoplasia

(2008) John E. Paes et al.   ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA

O-GlcNAc modulation at Akt1 Ser473 correlates with apoptosis of murine pancreatic β cells

(2008) Eun-Sil Kang et al.   EXPERIMENTAL CELL RESEARCH

Parathyroid Carcinoma

(2008) Claudio Marcocci et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Fatty Acid Synthase and AKT Pathway Signaling in a Subset of Papillary Thyroid Cancers

(2008) Shahab Uddin et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Highly Prevalent Genetic Alterations in Receptor Tyrosine Kinases and Phosphatidylinositol 3-Kinase/Akt and Mitogen-Activated Protein Kinase Pathways in Anaplastic and Follicular Thyroid Cancers

(2008) Zhi Liu et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Preclinical Targeting of the Type I Insulin-Like Growth Factor Receptor in Adrenocortical Carcinoma

(2008) Ferdous M. Barlaskar et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States

(2008) James C. Yao et al.   JOURNAL OF CLINICAL ONCOLOGY

The phosphatidylinositol 3-kinase/akt signaling pathway in medullary thyroid cancer

(2008) Susan C. Pitt et al.   SURGERY

Phosphatidylinositol 3-Kinase/Akt and Ras/Raf-Mitogen-Activated Protein Kinase Pathway Mutations in Anaplastic Thyroid Cancer

(2007) Libero Santarpia et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM